Lixte Biotechnology Holdings, Inc.
NASDAQ:LIXTBiotechnology
+$0.46 today
- Market cap
- $89.11M
- Beta
- 1.05
- P/E (TTM)
- -11.1
- EPS (TTM)
- -$0.67
Volume 0.61M
Average 0.12M
LIXT Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
Lixte Biotechnology Holdings, Inc.NASDAQ: LIXT
Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026
Net change in cash turns negative
Q1 FY2026 net change in cash was -$1.86M, compared with $345.75K a year earlier. Trailing-twelve-month net change in cash was $1.87M. Over 3 fiscal years it compounded at +97.3% a year.
Context
- Net change in cash increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly net change in cash holds near -$1.86M or moves back toward the trailing-twelve-month quarterly average of $466.49K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
USD · from the cash flow
- Latest · FY2025
- 4.07M USD
- Year-over-year change
- +228.5%
| Period | Period end | Net Change in Cash | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.07M | +228.5% |
| FY2024 | 2024-12-31 | (3.16M) | -175.2% |
| FY2023 | 2023-12-31 | (1.15M) | -317.1% |
| FY2022 | 2022-12-31 | 529.65K | +315.7% |
| FY2021 | 2021-12-31 | (245.52K) | — |
Net Change in Cash vs competitors
How LIXT compares with its peers on the latest reported figures
- LIXT's LTM Mar 2026 net change in cash of $1.87M is the smallest of the 2 companies compared; the peer median is $16.37M.
- Its year-over-year change of +191.9% is the highest of 2, against a peer median of +94.8%.
- Over three fiscal years its annual growth of +97.3% compares with a peer median of -51.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $16.37M | +94.8% | -51.7% | — | |
| LTM Mar 2026 | $1.87M | +191.9% | +97.3% | — | |
| Peer median (excluding LIXT) | $16.37M | +94.8% | -51.7% | — | |
Competitors are the stored peer set for LIXT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Lixte Biotechnology Holdings, Inc.
NASDAQ:LIXT
Intrinsic Alpha fair value
Locked
Current Price
$7.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.